Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome

BMC Immunology

Hanneke W M van Laarhoven²  Foekje F Stelma³  Gijs Bleijenberg¹  Lammy D Elving⁴  Carla M L van Herpen⁶  Sasja F Mulder⁶  Jeanette M Pots⁵  Ruurd Torensma⁵  I Jolanda M de Vries⁵  Hetty Prinsen⁶ 

[1] Expert Centre for Chronic Fatigue, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands;Department of Medical Oncology, Academic Medical Center University of Amsterdam, Amsterdam, the Netherlands;Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands;Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands;Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands;Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Geert Grooteplein Zuid 8, 6525, GA, Nijmegen, the Netherlands

关键词: Cellular immunity;    Humoral immunity;    Vaccination;    Influenza;    Chronic fatigue syndrome;   

Others  :  1077852
DOI  :  10.1186/1471-2172-13-71

 received in 2012-07-25, accepted in 2012-12-11,  发布年份 2012

【 摘 要 】

Background

Chronic fatigue syndrome (CFS) is a clinical condition characterized by severe and disabling fatigue that is medically unexplained and lasts longer than 6 months. Although it is possible to effectively treat CFS, the nature of the underlying physiology remains unclear. Various studies have sought evidence for an underlying disturbance in immunity. The aim of this study was to compare the humoral and cellular immune responses upon influenza vaccination in CFS patients and healthy controls.

Results

Identical antibody titers were observed in CFS patients and healthy controls. Patients and controls demonstrated similar seroprotection rates against all three virus-strains of the influenza vaccine, both pre- andpost-vaccination. Functional T cell reactivity was observed in both CFS patients and healthy controls. CFS patients showed a non-significant, numerically lower cellular proliferation at baseline compared to controls. Vaccination induced a significant increase in cellular proliferation in CFS patients, but not in healthy controls. Cytokine production and the number of regulatory T cells were comparable in patients and controls.

Conclusions

The humoral and cellular immune responses upon influenza vaccination were comparable in CFS patients and healthy controls. Putative aberrations in immune responses in CFS patients were not evident for immunity towards influenza. Standard seasonal influenza vaccination is thus justified and, when indicated, should be recommended for patients suffering from CFS.

【 授权许可】

   
2012 Prinsen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A, International Chronic Fatigue Syndrome Study Group: The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994, 121(12):953-959.
• [2]Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G: Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8(4):287-291.
• [3]Castell BD, Kazantzis N, Moss-Morris RE: Cognitive behavioral therapy and graded exercise for chronic fatigue syndrome: a meta-analysis. Clin Psychol: Sci Pract 2011, 18(4):311-324.
• [4]Chambers D, Bagnall AM, Hempel S, Forbes C: Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. J R Soc Med 2006, 99(10):506-520.
• [5]Malouff JM, Thorsteinsson EB, Rooke SE, Bhullar N, Schutte NS: Efficacy of cognitive behavioral therapy for chronic fatigue syndrome: a meta-analysis. Clin Psychol Rev 2008, 28(5):736-745.
• [6]Nijhof SL, Bleijenberg G, Uiterwaal CS, Kimpen JL, van de Putte EM: Effectiveness of internet-based cognitive behavioural treatment for adolescents with chronic fatigue syndrome (FITNET): a randomised controlled trial. Lancet 2012, 379(9824):1412-1418.
• [7]Price JR, Mitchell E, Tidy E, Hunot V: Cognitive behaviour therapy for chronic fatigue syndrome in adults. Cochrane Database Syst Rev 2008, (3):CD001027.
• [8]Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, van der Wilt GJ, Spinhoven P, van der Meer JW: Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet 2001, 357(9259):841-847.
• [9]Stulemeijer M, de Jong LW, Fiselier TJ, Hoogveld SW, Bleijenberg G: Cognitive behaviour therapy for adolescents with chronic fatigue syndrome: randomised controlled trial. BMJ 2005, 330(7481):14.
• [10]Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G: Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001, 286(11):1360-1368.
• [11]Brooks JC, Roberts N, Whitehouse G, Majeed T: Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome. Br J Radiol 2000, 73(875):1206-1208.
• [12]Chaudhuri A, Condon BR, Gow JW, Brennan D, Hadley DM: Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome. Neuroreport 2003, 14(2):225-228.
• [13]de Lange FP, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JW, Toni I: Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage 2005, 26(3):777-781.
• [14]de Lange FP, Koers A, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JW, Toni I: Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain 2008, 131(Pt 8):2172-2180.
• [15]Mathew SJ, Mao X, Keegan KA, Levine SM, Smith EL, Heier LA, Otcheretko V, Coplan JD, Shungu DC: Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed 2009, 22(3):251-258.
• [16]Puri BK, Counsell SJ, Zaman R, Main J, Collins AG, Hajnal JV, Davey NJ: Relative increase in choline in the occipital cortex in chronic fatigue syndrome. Acta Psychiatr Scand 2002, 106(3):224-226.
• [17]Tomoda A, Miike T, Yamada E, Honda H, Moroi T, Ogawa M, Ohtani Y, Morishita S: Chronic fatigue syndrome in childhood. Brain Dev 2000, 22(1):60-64.
• [18]Schillings ML, Kalkman JS, van der Werf SP, van Engelen BG, Bleijenberg G, Zwarts MJ: Diminished central activation during maximal voluntary contraction in chronic fatigue syndrome. Clin Neurophysiol 2004, 115(11):2518-2524.
• [19]Ortega-Hernandez OD, Shoenfeld Y: Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Ann N Y Acad Sci 2009, 1173:600-609.
• [20]Nancy AL, Shoenfeld Y: Chronic fatigue syndrome with autoantibodies–the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 2008, 8(1):52-55.
• [21]Rosenblum H, Shoenfeld Y, Amital H: The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. Infect Dis Clin North Am 2011, 25(4):851-863.
• [22]Sleigh KM, Danforth DG, Hall RT, Fleming JA, Stiver HG: Double-blind, randomized study of the effects of influenza vaccination on the specific antibody response and clinical course of patients with chronic fatigue syndrome. Can J Infect Dis 2000, 11(5):267-273.
• [23]Taga K, Tosato G: IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992, 148(4):1143-1148.
• [24]Levings MK, Sangregorio R, Roncarolo MG: Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001, 193(11):1295-1302.
• [25]Coyle AJ, Gutierrez-Ramos JC: The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001, 2(3):203-209.
• [26]Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
• [27]Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, et al.: BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003, 4(7):670-679.
• [28]Dittner AJ, Wessely SC, Brown RG: The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 2004, 56(2):157-170.
• [29]Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G: Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994, 38(5):383-392.
• [30]Mulder SF, Jacobs JF, Olde Nordkamp MA, Galama JM, Desar IM, Torensma R, Teerenstra S, Mulders PF, Vissers KC, Punt CJ, et al.: Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin Cancer Res 2011, 17(13):4541-4549.
• [31]de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD: Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003, 115:63-73.
• [32]Pollyea DA, Brown JM, Horning SJ: Utility of influenza vaccination for oncology patients. J Clin Oncol 2010, 28(14):2481-2490.